Related Experiment Video
Updated: Jun 22, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Potential impact of early antiretroviral therapy on transmission
David Pao1, Deenan Pillay, Martin Fisher
1HIV/GUM Research Department, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Purpose Of Review:
In this review, we will discuss the potential of early highly active antiretroviral therapy (HAART) to reduce the sexual transmission of HIV on an individual and population level. We will focus on the biological plausibility and behavioural factors associated with HAART use and interventions that might influence such a strategy.
Recent Findings:
Empiric and phylogenetic studies support the view that recent HIV infection is a highly infectious disease stage. Evidence increasingly demonstrates that individuals on fully suppressive HAART are significantly less likely to transmit HIV to sexual partners and some even suggest that such individuals cannot transmit HIV. Changes in risk behaviour are associated with the availability of HAART but behavioural studies offer contradictory observations regarding the direction and magnitude of these changes. This in turn makes the intricate assumptions and therefore outcomes of many complex mathematical modelling studies less secure. Furthermore, there is evidence that it is those individuals with undiagnosed HIV infection who contribute significantly to onward sexual transmission.
Summary:
At an individual level, HAART will reduce viral load and, therefore, infectiousness, although whether to zero or not remains controversial. At a population level, if recent infection and undiagnosed infections continue to drive onward transmission, earlier treatment will only alter the pandemic if accompanied by an improvement in diagnosing the undiagnosed and recognizing recent infection.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Inhibitors of Virion Maturation and Assembly
Amebiasis
Retroviruses
Inhibitors of Viral Protein Synthesis

